Prostate cancer tumor cells harboring a heterozygous deletion of FANCI were selectively eradicated by chemotherapy, while those with intact FANCI resisted chemotherapy, suggesting that FANCI could be a possible therapeutic target to convert resistant cancer cells to an eradicable state. The gene discussed is FANCI; the disease is prostate cancer.